Enrique Diaz-Guzman

Enrique Diaz-Guzman

Auto-generated profile, based on publicly available information

Enrique Diaz-Guzman

From the Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Translational Research
Verified
Journal Article
Closed access
SAShambhu Aryal
Shambhu Aryal
EDEnrique Diaz-Guzman
Enrique Diaz-Guzman
DMDavid M. Mannino
David M. Mannino

1 March 2013 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
CHCharles W. Hoopes
Charles W. Hoopes
JKJasleen Kukreja
Jasleen Kukreja
JGJeffery Golden
Jeffery Golden
DDDaniel L. Davenport
Daniel L. Davenport
EDEnrique Diaz-Guzman
Enrique Diaz-Guzman
JZJoseph B. Zwischenberger
Joseph B. Zwischenberger

1 March 2014 in Clinics in Chest Medicine
Verified
Journal Article
Closed access
EDEnrique Diaz-Guzman
Enrique Diaz-Guzman
DMDavid M. Mannino
David M. Mannino

8 December 2011 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
PDF file
EDEnrique Diaz-Guzman
Enrique Diaz-Guzman
MKMehdi Khosravi
Mehdi Khosravi
DMDavid M. Mannino
David M. Mannino
Background: COPD and asthma are common diseases in the U.S. population and can coexist. Our goal was to determine the prevalence of self-reported, physician-diagnosed asthma and COPD in a sample of the U.S. population and their association with lung function impairment and mortality. Methods: We used baseline data from NHANES III and the follow-up mortality data. We used logistic regression and Cox Proportional Hazards models, adjusting for age, sex, race/ethnicity, education level, smoking status, and disease stage. Results: The sample consisted of 15,203 subjects, of whom 4,542 died during the follow-up period. Coexisting COPD and asthma was reported by 357 (2.7%), COPD by 815 (5.3%), and asthma by 709 (5.3%). Subjects with both conditions had a higher proportion of obstruction (30.9%) than those with COPD (24.3%), asthma (13.3%), or no lung disease (5.4%). In survival models adjusting for all factors except baseline lung function, coexisting COPD and asthma had the highest risk for mortality (Hazard Ratio [HR] 1.83, 95% confidence interval [CI] 1.34, 2.49), followed by COPD only (HR 1.44, 95% CI 1.28, 1.62), and asthma only (HR 1.16, 95% CI 0.94, 1.42). These affects were attenuated after controlling for baseline lung function: coexisting asthma and COPD (HR 1.45, 95% CI 1.06, 1.98), COPD only (1.28, 95% CI 1.13, 1.45), and asthma only (HR 1.04, 95% CI 0.85, 1.27). Conclusion: In this analysis, subjects who report coexisting asthma and COPD have a higher risk of obstruction on spirometry and a higher risk of death during follow-up.

1 December 2011 in Respiratory Research
Verified
Journal Article
Open access
PDF file
DMDavid M Mannino
David M Mannino
EDEnrique Diaz-Guzman
Enrique Diaz-Guzman
SBSonia Buist
Sonia Buist
Chronic obstructive pulmonary disease (COPD) is supposed to be classified on the basis of post-bronchodilator lung function. Most longitudinal studies of COPD, though, do not have post-bronchodilator lung function available. We used pre-and post bronchodilator lung function data from the Lung Health Study to determine whether these measures differ in their ability to predict mortality.

1 January 2013 in ASAIO Journal
Verified
Journal Article
Closed access
EDEnrique Diaz-Guzman
Enrique Diaz-Guzman
CHCharles W. Hoopes
Charles W. Hoopes
JZJoseph B. Zwischenberger
Joseph B. Zwischenberger
The use of extracorporeal membrane oxygenation (ECMO) as a bridge to lung transplantation was reported for the first time more than three decades ago; nevertheless, its use in lung transplantation was largely abandoned because of poor patient survival and frequent complications. The outcomes of patients bridged to lung transplantation using ECMO have substantially improved in the last 5 years. Recent advances in extracorporeal life support technology now allow patients with end-stage lung disease to be successfully supported for prolonged periods of time, preventing the use of mechanical ventilation and facilitating physical rehabilitation and ambulation while the patients awaits lung transplantation. This review briefly describes the evolution of ECMO use in lung transplantation and summarizes the available technology and current approaches to provide ECMO support.